Table 1 Clinical and demographic data in the present series.

From: PET amyloid in normal aging: direct comparison of visual and automatic processing methods

 

Gender

Total

p Value

Female

Male

N

96

59

155

 

Age at Amy PET

77.9 ± 4.2

78.2 ± 4.4

78.0 ± 4.3

0.680

Education (year)

   

< 0.01

< 9

22 (22.9%)

1 (1.7%)

23 (14.8%)

 

9–12

45 (46.9%)

26 (44.1%)

71 (45.8%)

 

> 12

29 (30.2%)

32 (54.2%)

61 (39.4%)

 

MMSE at baseline

28.5 ± 1.4

28.5 ± 1.6

28.5 ± 1.5

0.994

APOE4

   

0.663

Negative

84 (87.5%)

53 (89.8%)

137 (88.4%)

 

Positive

12 (12.5%)

6 (10.2%)

18 (11.6%)

 

Visual Score Amy PETa

   

0.775

Negative

67 (69.8%)

40 (67.8%)

107 (69.0%)

 

Positive

29 (30.2%)

19 (32.2%)

48 (31.0%)

 
  1. aSeventy-seven 18F-Florbetapir- (Amyvid) and seventy-eight 18F-Flutemetamol-PET (Vizamyl).
Back to article page